Prosonix Extends Series B Financing Round to £17.1M
Dr Karl Nägler, a Venture Capital Partner at Gimv, will also join the Prosonix board as a Non-executive Director.
The proceeds of the financing will be used to progress the Company’s emerging proprietary product pipeline of excipient-free, drug-only inhalable mono- and combination therapies. Prosonix applies its proprietary ultrasonic particle engineering technology to existing drug compounds in low-cost generic devices, utilising where possible the new regulatory guidelines for accelerated approval.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.